Scleroderma (systemic sclerosis): the GP guide to organ surveillance

Systemic sclerosis affects approximately one person in every 6,000–10,000 Australians, with women outnumbering men by four to nine to one and peak onset between age 30 and 60 (RACGP; ARA). Despite its rarity, it carries a standardised mortality ratio of around 3.5 — pulmonary arterial hypertension and interstitial lung disease account for more than 60% of SSc-related deaths, and scleroderma renal crisis was uniformly fatal until ACE inhibitors changed that picture. ATSI populations carry a higher prevalence and worse outcomes than the general Australian population, and care should be coordinated through NACCHO services where appropriate. The GP role is to maintain the annual surveillance calendar, recognise and act immediately on renal crisis, support the specialist team with ongoing prescribing and monitoring, and address the disease’s substantial psychological burden.

A. Core clinical — subtypes, antibodies, and first-pass workup

Disease classification

LeRoy and Medsger’s 1988 classification remains the clinical backbone, refined by the 2013 ACR/EULAR criteria:

Limited cutaneous SSc (lcSSc): Skin thickening confined to distal to elbows and knees plus face. Raynaud’s phenomenon typically precedes skin changes by years or decades. The CREST features — Calcinosis cutis (calcium deposits under skin), Raynaud’s, Esophageal dysmotility, Sclerodactyly (tapered, thickened digits), and Telangiectasias — are characteristic. Progression is slow. The dominant late complication is pulmonary arterial hypertension, appearing in 10–15% of patients, typically ten to twenty years after diagnosis. Anti-centromere antibody (ACA) is the marker.

Diffuse cutaneous SSc (dcSSc): Skin thickening proximal to elbows and knees, extending to trunk. Raynaud’s-to-skin interval is short (under 12 months). Rapid progression in the first three to five years. Interstitial lung disease affects around 40–75% of dcSSc patients; scleroderma renal crisis threatens the first five years. Anti-Scl-70 (topoisomerase I) and anti-RNA polymerase III are the key antibodies.

SSc sine scleroderma: Visceral disease (ILD, PAH, SRC) with disease-specific antibody but no skin thickening — approximately 5% of cases, often diagnosed late.

The antibodies and what they predict

• Anti-centromere (ACA): lcSSc; PAH risk; SRC uncommon; good long-term prognosis.
• Anti-topoisomerase I (Scl-70): dcSSc; ILD risk; poorer prognosis.
• Anti-RNA polymerase III (anti-RNApol III): dcSSc; highest SRC risk; paraneoplastic cancer association (breast, lung, ovarian — cancer appearing within three years of SSc onset in ~15% of anti-RNApol III positive patients; cancer screen mandatory).
• ANA: positive in over 95% of patients; used as a screening test.

First-pass workup (GP-initiated)

When SSc is suspected — puffy fingers, Raynaud’s, tight skin, nailfold capillary changes — order:

• ANA, ENA panel requesting anti-Scl-70, anti-centromere, and anti-RNA polymerase III explicitly (anti-RNApol III is not always included in standard ENA panels and must be specifically requested) — MBS item 73529.
• FBC + film, UEC, LFT, CK, CRP, ESR — MBS item 65070 or 66536. Microangiopathic haemolysis on the blood film is a clue for active SRC.
• ECG — MBS item 11700 — right ventricular strain pattern.
• Spirometry and DLCO — MBS items 11506 + 11512 — a restrictive pattern with low DLCO suggests ILD; isolated low DLCO with preserved volumes suggests early PAH.
• Echocardiogram — MBS item 11941 — for estimated pulmonary artery systolic pressure, RV size, and pericardial effusion.
• HRCT chest — MBS item 56022 — baseline; NSIP pattern is most common SSc-ILD.
• Blood pressure at every visit + urinalysis — SRC vigilance; rising blood pressure with haematuria or proteinuria in a dcSSc patient is a medical emergency.

Refer to rheumatology once SSc is suspected — do not wait for antibody results.

B. The two life-threatening organ complications

Scleroderma renal crisis — act immediately

SRC presents as sudden accelerated or malignant hypertension (systolic above 150 mmHg, often much higher) with acute kidney injury, frequently accompanied by microangiopathic haemolytic anaemia and retinal changes. It occurs most commonly in early dcSSc (first three to five years), anti-RNA polymerase III positive patients, and patients taking prednisolone above 15 mg daily.

The treatment rule is absolute: Start captopril 6.25–12.5 mg orally, titrate rapidly to achieve blood pressure control, continuing around the clock. Enalapril is an alternative. ACE inhibitors are life-saving — Steen 1990 documented the transformation from 75% one-year mortality to under 20%. Continue even as creatinine rises — this is expected and does not indicate treatment failure in the acute phase.

The prophylaxis prohibition is equally absolute: Do not prescribe ACE inhibitors preventively in normotensive SSc patients. The GENISOS cohort (Hudson 2014) found that prophylactic ACE inhibition was associated with hazard ratios of 2.4 for worse renal outcomes — the proposed mechanism is masking of early SRC while abolishing the compensatory renin surge.

Minimise corticosteroid use in SSc; prednisolone above 15 mg daily is a strong SRC trigger.

Interstitial lung disease — surveillance and treatment

SSc-ILD is the most common cause of SSc-related death. It affects 40–75% of dcSSc patients and a smaller proportion of lcSSc, usually appearing in the first five years of diffuse disease. The EULAR 2024 guideline and ACR 2024 ILD guideline recommend:

First-line immunosuppression: Mycophenolate mofetil 2–3 g daily — SLS-II (Tashkin, Lancet Respir Med 2016) demonstrated non-inferiority to intravenous cyclophosphamide at 24 months with substantially lower toxicity. PBS Authority required; rheumatology or respiratory initiation.

Antifibrotic combination: Nintedanib (Ofev) PBS Section 100 Authority for SSc-ILD — SENSCIS (Distler, NEJM 2019) showed a 44% reduction in annual FVC decline versus placebo. Diarrhoea is the main side effect (75% of patients). Often combined with mycophenolate. Does not reverse existing fibrosis but significantly slows progression.

For rapidly progressive or fulminant disease: IV cyclophosphamide pulses, tocilizumab (emerging evidence from focuSSced and faSScinate trials), rituximab.

For carefully selected severe progressive dcSSc: Autologous haemopoietic stem-cell transplantation — superior event-free and overall survival versus cyclophosphamide per ASTIS (van Laar, JAMA 2014) and SCOT (Sullivan, NEJM 2018). Treatment-related mortality is 5–10%; this is a specialist decision at a tertiary BMT centre.

C. Treatment by organ system

Raynaud’s phenomenon and digital ulcers: Nifedipine MR 30–60 mg daily is first-line; add sildenafil 50 mg twice daily if insufficient. Bosentan is PBS Authority for prevention of recurrent digital ulcers in SSc — the indication established by the RAPIDS-1 and RAPIDS-2 trials. IV iloprost is reserved for critical ischaemia or impending gangrene (hospital administration). Topical GTN 0.2% gel can treat individual severely ischaemic digits.

Pulmonary arterial hypertension: Upfront dual oral therapy — an endothelin receptor antagonist (bosentan, macitentan, or ambrisentan) plus a PDE5 inhibitor (sildenafil or tadalafil) — is now the standard of care per AMBITION (Galiè, NEJM 2015), which demonstrated 50% reduction in clinical failure versus monotherapy. All PAH-targeted therapies are on the PBS under Section 100 Highly Specialised Drugs with specialist authority.

Skin: Methotrexate 15–25 mg weekly for early progressive dcSSc skin disease — PBS Authority Streamlined. Emollients daily, avoiding alkaline soaps. UVA1 phototherapy for severe refractory sclerosis at specialist centres.

Gastrointestinal: Long-term PPI (omeprazole or esomeprazole) for GORD and oesophageal protection — general schedule. Prokinetics (metoclopramide 10 mg three times daily, or low-dose erythromycin 50–100 mg three times daily as a motilin agonist) for gastroparesis and early satiety. Rotating antibiotics (rifaximin, ciprofloxacin, metronidazole) for small-bowel bacterial overgrowth. Endoscopic argon plasma coagulation for gastric antral vascular ectasia (“watermelon stomach”) via gastroenterology.

Musculoskeletal: Hydroxychloroquine 5 mg/kg/day (PBS Authority Streamlined) for arthralgia and skin. Physiotherapy for skin stretching exercises, joint protection, and contracture prevention. OT for adaptive devices.

Vaccinations: NIP-funded influenza, COVID-19, PCV20, and Shingrix (recombinant zoster — safe on immunosuppressants) — schedule before starting immunosuppression where possible. Avoid all live vaccines (MMR, varicella, yellow fever, BCG) on immunosuppressants.

D. Australian operations

Specialist care pathway: Rheumatology leads the multidisciplinary team; co-management with respiratory medicine (ILD), cardiology (PAH), nephrology (SRC), gastroenterology (dysmotility), and dietitian is standard. Major Australian centres with multidisciplinary scleroderma clinics include Royal Prince Alfred Hospital Sydney, Royal Melbourne Hospital, Royal Adelaide Hospital, Royal Brisbane and Women’s Hospital, and Sir Charles Gairdner Hospital Perth.

MBS items: GP consultations 23/36/44; rheumatology 132/133; GPCCMP 965/967; MHCP 2715/2717; ATSI annual health assessment 715; spirometry 11506; DLCO 11512; echo 11941; HRCT chest 56022.

PBS: Mycophenolate, methotrexate, hydroxychloroquine (Authority); nintedanib Section 100 Authority for SSc-ILD; PAH drugs Section 100 HSD with specialist authority; bosentan PBS Authority for recurrent digital ulcers; captopril/enalapril general schedule (SRC).

Patient organisations: Scleroderma Australia provides state-based peer support groups and an annual conference; the Lung Foundation Australia offers pulmonary rehabilitation programs and ILD patient resources.

E. Special populations

Pre-conception and pregnancy: dcSSc, anti-Scl-70 positivity, anti-RNA polymerase III, and especially SSc-associated PAH all carry substantially increased maternal and fetal risk. PAH in pregnancy carries maternal mortality approaching 50% and pregnancy is generally contraindicated until disease is stable for more than two years. ACE inhibitors are teratogenic — switch to nifedipine or labetalol for blood pressure management before conception. Refer all SSc patients planning pregnancy to a high-risk obstetric service (maternal-fetal medicine).

ATSI patients: Higher prevalence and documented worse outcomes in ATSI populations require culturally safe care models. Use MBS item 715 for annual ATSI health assessment; coordinate with Aboriginal Health Workers and NACCHO services for medication management and specialist access.

Anti-RNA polymerase III positive patients require cancer screening every three years — the paraneoplastic association with breast, lung, and ovarian cancer appearing within three years of SSc onset is clinically important. Age-appropriate cancer screening should be actively co-ordinated by the GP.

When to escalate

Same-day or emergency hospital referral: New accelerated hypertension plus acute kidney injury in a dcSSc patient (suspected SRC — start ACE inhibitor immediately and call the renal/rheumatology team); critical digital ischaemia or gangrene; new severe dyspnoea with oxygen desaturation (ILD progression or PAH crisis); syncope with right ventricular strain on ECG (PAH crisis); haemodynamically significant pericardial effusion.

Routine rheumatology referral: Any patient with suspected SSc, even before antibody confirmation — the diagnosis should be made and monitoring initiated by a specialist.

Semi-urgent specialist: New dyspnoea or declining spirometry (respiratory); new onset atrial fibrillation, syncope, or falling six-minute walk distance (cardiology/PAH); nausea, weight loss, malabsorption, or uncontrolled GORD (gastroenterology).

What this article is and is not

This article provides educational information about systemic sclerosis for patients and clinicians. It is not a substitute for specialist diagnosis and management. Scleroderma is a complex multisystem disease requiring coordinated specialist care — GPs play a critical role in surveillance, early complication detection, and patient support, working within a team led by rheumatology. Any patient with new accelerated hypertension and acute kidney injury in the context of scleroderma should be treated as a medical emergency.

---

Sources cited

• RACGP — Scleroderma: an approach for general practice
• Therapeutic Guidelines (eTG) — Rheumatology: Systemic sclerosis
• Australian Rheumatology Association — Systemic sclerosis position statement
• EULAR 2024 update of recommendations for SSc — Del Galdo ARD 2024
• EULAR 2017 update — Kowal-Bielecka ARD 2017
• ACR 2024 guideline for ILD in systemic autoimmune rheumatic diseases
• LeRoy-Medsger 1988 classification — J Rheumatol
• 2013 ACR/EULAR classification criteria — van den Hoogen ARD 2013
• SLS-II — Tashkin et al. MMF vs cyclophosphamide in SSc-ILD. Lancet Respir Med 2016
• SENSCIS — Distler et al. Nintedanib in SSc-ILD. NEJM 2019
• focuSSced — Khanna et al. Tocilizumab in SSc-ILD. Lancet Respir Med 2020
• AMBITION — Galiè et al. Upfront combination ERA+PDE5i in PAH. NEJM 2015
• GRIPHON — Sitbon et al. Selexipag in PAH. NEJM 2015
• Steen VD — ACE inhibitors in scleroderma renal crisis. Ann Intern Med 1990
• GENISOS — Hudson et al. Prophylactic ACEi and renal outcomes. Am J Med 2014
• RAPIDS-1 — Korn et al. Bosentan for digital ulcers. Arthritis Rheum 2004
• RAPIDS-2 — Matucci-Cerinic et al. Bosentan for digital ulcers. ARD 2011
• ASTIS — van Laar et al. Autologous HSCT vs cyclophosphamide. JAMA 2014
• SCOT — Sullivan et al. Myeloablative HSCT in dcSSc. NEJM 2018
• Australian Medicines Handbook (AMH)
• PBS — mycophenolate, nintedanib, bosentan, PAH drugs, captopril, methotrexate, hydroxychloroquine
• MBS item 11506 — spirometry
• MBS item 11512 — DLCO
• MBS item 11941 — echocardiogram
• MBS item 56022 — HRCT chest
• Scleroderma Australia
• Lung Foundation Australia — SSc-ILD and pulmonary fibrosis
• HealthDirect — Scleroderma
• Better Health Channel — Scleroderma